Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$216 Mln
P/E Ratio
--
P/B Ratio
3.25
Industry P/E
--
Debt to Equity
0.16
ROE
-1.4 %
ROCE
-97.92 %
Div. Yield
0 %
Book Value
2.07
EPS
-1.72
CFO
$-102.13 Mln
EBITDA
$-140.14 Mln
Net Profit
$-107.12 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Candel Therapeutics Inc (CADL)
| -42.34 | -37.90 | -29.11 | -15.31 | 0.85 | -- | -- |
|
BSE Sensex
| 1.99 | 3.77 | 4.29 | 8.22 | 11.74 | 20.16 | 11.15 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
|
|---|---|---|---|
|
Candel Therapeutics Inc (CADL)
| 481.99 | -17.88 | -77.11 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 37.32 | 9,808.03 | 20.22 | 23.13 | |
| 302.07 | 8,956.09 | 22.08 | 58.42 | |
| 26.91 | 9,559.25 | -- | -28.77 | |
| 104.61 | 10,030.35 | 30.81 | 14.16 |
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase III clinical trials for the treatment of prostate cancer; Phase II clinical trials for... the treatment of pancreatic cancer; and Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the"enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts. Address: 117 Kendrick Street, Needham, MA, United States, 02494 Read more
President, CEO & Director
Dr. Paul-Peter Tak FMEDSCI, M.D., Ph.D.
President, CEO & Director
Dr. Paul-Peter Tak FOCIS, M.D., Ph.D.
Headquarters
Needham, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Candel Therapeutics Inc (CADL) stood at $ 107 Mln as on 31-Dec-24
The share price of Candel Therapeutics Inc (CADL) is $5.01 (NASDAQ) as of 24-Apr-2025 12:40 EDT. Candel Therapeutics Inc (CADL) has given a return of 0.85% in the last 3 years.
Candel Therapeutics Inc (CADL) has a market capitalisation of $ 216 Mln as on 22-Apr-2025. As per Value Research classification, it is a Small Cap company.
Since, TTM earnings of Candel Therapeutics Inc (CADL) is negative, P/E ratio is not available.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Candel Therapeutics Inc (CADL) and enter the required number of quantities and click on buy to purchase the shares of Candel Therapeutics Inc (CADL).
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase III clinical trials for the treatment of prostate cancer; Phase II clinical trials for the treatment of pancreatic cancer; and Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In addition, it develops the"enLIGHTEN Discovery Platform, a systematic, iterative herpes simplex virus based discovery platform leveraging human biology and advanced analytics to create new viral immunotherapy candidates for solid tumors. The company was formerly known as Advantagene, Inc. and changed its name to Candel Therapeutics, Inc. in November 2020. Candel Therapeutics, Inc. was incorporated in 2003 and is headquartered in Needham, Massachusetts. Address: 117 Kendrick Street, Needham, MA, United States, 02494
The CEO & director of Dr. Paul-Peter Tak FMEDSCI, M.D., Ph.D.. is Candel Therapeutics Inc (CADL), and CFO & Sr. VP is Dr. Paul-Peter Tak FOCIS, M.D., Ph.D..
There is no promoter pledging in Candel Therapeutics Inc (CADL).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,012
|
|
|
990
|
|
|
974
|
|
|
896
|
| Candel Therapeutics Inc (CADL) | Ratios |
|---|---|
|
Return on equity(%)
|
-139.56
|
|
Operating margin(%)
|
--
|
|
Net Margin(%)
|
--
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Candel Therapeutics Inc (CADL) was $0 Mln.
$0.25
(
